Free tools Windows power users keep installed
One-click scans. No signup required.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
COX inhibitors are not yet in a proven clinical comeback. Selective COX-2 drugs remain clinically relevant and continue to be investigated, but the available evidence does not identify a newly approved medicine, a named returning candidate, or a recent milestone that would justify saying the class has definitively returned.
The reason for renewed interest is a familiar trade-off: targeting COX-2 can reduce some gastrointestinal injury associated with nonselective NSAIDs, yet cardiovascular and kidney risks remain dependent on the drug, dose, duration, patient and comparator. The best-supported modern comparison, the PRECISION arthritis trial, found similar rates of its primary cardiovascular outcome for celecoxib, naproxen and ibuprofen under the study’s specific conditions—not zero risk.
What “COX inhibitor” means
COX stands for cyclooxygenase, an enzyme system involved in making prostaglandins. Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase to reduce pain and inflammation and to lower fever. “COX inhibitor” is therefore a broad pharmacologic category, not the name of one medicine.
Two practical groupings matter:
| Group | Examples in the available evidence | Pharmacologic aim | Main trade-off |
|---|---|---|---|
| Nonselective NSAIDs | Ibuprofen, naproxen | Inhibit both COX-1 and COX-2 to varying degrees | Potential gastrointestinal injury alongside cardiovascular and renal concerns |
| More COX-2-selective inhibitors | Celecoxib | Emphasize COX-2 inhibition in an attempt to improve gastrointestinal tolerability | COX-2 selectivity does not remove cardiovascular or renal risk |
Selectivity is a relative property, not an on/off safety switch. A drug can favor COX-2 at one dose and become less selective at another, while the patient’s baseline risk and treatment duration also change the balance of benefits and harms.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
Why researchers keep revisiting COX-2 selectivity
The central rationale is gastrointestinal tolerability. Some nonselective NSAID effects on COX-1 are associated with loss of protective prostaglandin activity in the gastrointestinal tract. Developing a medicine that inhibits COX-2 more than COX-1 was intended to preserve more of that protection while retaining anti-inflammatory action.
That strategy created a second safety question. COX-2-related prostaglandin pathways also participate in vascular and kidney physiology. A medicine that looks attractive from a stomach-outcome perspective can still produce clinically important blood-pressure, fluid-retention, cardiovascular or renal problems in susceptible people. The resulting question is not “Are COX-2 inhibitors safe?” but “For this patient, at this exposure, compared with which alternative, what outcome changes?”
A 2024 review, NSAIDs between past and present; a long journey towards an ideal COX-2 inhibitor lead in RSC Advances, describes continuing work on selective COX-2 compounds. It is a review of the field, not evidence that an unnamed candidate has returned to routine practice or obtained a new approval.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →What the PRECISION trial actually found
The most useful modern head-to-head evidence in the available material comes from the randomized PRECISION trial, reported in the New England Journal of Medicine in 2016. It enrolled patients with arthritis and compared celecoxib, naproxen and ibuprofen. In the intention-to-treat analysis, the trial’s primary cardiovascular composite occurred at the following proportions:
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
| Assigned treatment | Primary cardiovascular composite | What the figure represents |
|---|---|---|
| Celecoxib | 2.3% | Participants assigned celecoxib who experienced the prespecified composite during the trial |
| Naproxen | 2.5% | Participants assigned naproxen who experienced the same composite |
| Ibuprofen | 2.7% | Participants assigned ibuprofen who experienced the same composite |
Celecoxib met the trial’s noninferiority comparisons with naproxen and ibuprofen for that primary outcome. Noninferiority means the study ruled out a prespecified amount of excess risk under its design; it does not prove that celecoxib is superior, universally safer or risk-free.
How to read those percentages
- They are trial outcome proportions, not an individualized prediction for a particular reader.
- They apply to the trial’s arthritis population, treatment regimens, follow-up, endpoint definition and intention-to-treat analysis.
- They do not establish that the same relationship holds at every dose, for every treatment duration, in people with different cardiovascular or kidney risk, or for every other NSAID.
- The small numerical differences should not be treated as a ranking that ignores confidence intervals, adherence, discontinuation and the study’s noninferiority design.
The result is important because it challenges a simplistic assumption that a COX-2-selective option must necessarily have worse cardiovascular outcomes than the compared nonselective drugs. It does not erase the reason cardiovascular monitoring remains part of NSAID prescribing.
The safety trade-off: gastrointestinal, cardiovascular and renal outcomes
Gastrointestinal outcomes
COX-2 selectivity was pursued partly to reduce gastrointestinal injury associated with some nonselective NSAID exposure. That is a potential tolerability advantage, not a guarantee. Gastrointestinal risk still depends on dose, duration, previous ulcer or bleeding history, age, other medicines and the specific endpoint being measured.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Cardiovascular outcomes
Cardiovascular risk can include several different outcomes rather than one universal measure. A trial’s composite might combine events such as cardiovascular death, nonfatal myocardial infarction or nonfatal stroke, while another study may use a different definition. Comparing percentages without checking the endpoint can create a false impression of precision.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
The PRECISION figures show that, in its selected population and regimen, celecoxib was noninferior to naproxen and ibuprofen for the primary cardiovascular composite. They do not show that a person with established cardiovascular disease faces no added risk, nor do they justify changing treatment without clinical advice.
Renal outcomes
Kidney effects are a separate axis from gastrointestinal and cardiovascular outcomes. COX inhibition can alter prostaglandin-dependent kidney blood flow and fluid handling, so renal risk may become more important with dehydration, pre-existing kidney impairment, heart failure, older age or interacting medicines. A gastrointestinal benefit cannot be counted as a complete safety assessment when renal outcomes were not the endpoint under discussion.
Why dose and comparison design change the answer
The 2022 review Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials, by Carl-Olav Stiller and Paul Hjemdahl of Karolinska Institutet and Karolinska University Hospital, emphasizes two interpretive rules.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Dose-response matters
Risk is not a fixed label attached to a molecule. Higher exposure can change selectivity, prostaglandin suppression and adverse-event rates. A result obtained with a moderate regimen cannot automatically be applied to a higher dose, prolonged use or a different formulation. Any credible “comeback” claim should state the dose tested and whether the dose is proposed for routine use.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
Fair comparisons matter
A fair comparison matches the clinical question. If one study compares a selective drug with a nonselective NSAID in arthritis, its findings do not automatically answer whether the selective drug is preferable to acetaminophen, topical therapy, a non-drug intervention or no treatment. The comparator, background therapy, follow-up and outcome definition all affect the conclusion.
How to test a claim that COX inhibitors are “back”
When a headline uses comeback language, use this checklist before accepting it:
- Name the candidate. A real clinical development should identify the molecule, sponsor or research program. A general review of selective COX-2 chemistry is not a new approval.
- Check the regulatory event. Look for a dated authorization, expanded indication or label change and note the country or region. The available evidence does not establish such an event for a newly returning candidate.
- Separate laboratory progress from patient evidence. Enzyme assays, animal studies and medicinal-chemistry leads can show selectivity without demonstrating clinical benefit or safety.
- Read the endpoint. “Fewer stomach events” and “no excess cardiovascular risk” are different claims. Identify whether the outcome was gastrointestinal, cardiovascular, renal, pain-related or a composite.
- Carry the dose and duration with the result. Do not quote a percentage without the regimen and follow-up that produced it.
- Match the population. Age, arthritis type, baseline cardiovascular disease, kidney function and concurrent medicines can change absolute risk.
What is and is not established about a present-day comeback
The current evidence supports a narrower conclusion than the headline suggests:
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Clear out junk files and repair common Windows errors3Scan for outdated or missing drivers - takes under a minute- COX inhibitors remain an active clinical and research subject.
- Selective COX-2 development continues, according to the 2024 review.
- The PRECISION trial provides reassuring comparative cardiovascular evidence for celecoxib under its study conditions, with primary-composite rates of 2.3% for celecoxib, 2.5% for naproxen and 2.7% for ibuprofen.
- No specific new COX-2 candidate, recent approval or clearly documented return to clinical use is identified in the available material.
- Current regulatory status and geographic availability for any newly returning candidate therefore remain unresolved.
That distinction matters for readers because “research interest,” “late-stage development,” “regulatory approval” and “routine prescribing” are different milestones. Treating them as interchangeable turns a cautious scientific update into an unsupported comeback story.
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
Questions to take to a clinician
If you are offered an NSAID or are reading about a selective COX-2 option, ask which outcome the treatment is intended to improve and which risks are most relevant to you. Useful questions include:
- Is the proposed drug nonselective or relatively COX-2 selective?
- What dose and duration are planned, and what is the reassessment point?
- How do my cardiovascular, gastrointestinal and kidney risks affect the choice?
- Which medicines, supplements or illnesses could increase adverse effects?
- What symptoms or test results should prompt a call or urgent care?
- What alternatives exist if the expected benefit does not occur?
Do not use the PRECISION percentages as a personal risk calculator, and do not start, stop or switch an NSAID solely because a headline describes a comeback.
Bottom line
COX inhibitors have not demonstrated a single, identifiable comeback event. They have demonstrated something more nuanced: selective COX-2 inhibition remains a legitimate design strategy, and comparative evidence does not support assuming that celecoxib is automatically more dangerous cardiovascularly than naproxen or ibuprofen in every setting. The unresolved work is to define, for each drug and patient, whether any gastrointestinal advantage outweighs cardiovascular and renal risks at the dose and duration actually used.
Quick Recap
Sources informing this explainer
- NSAIDs between past and present; a long journey towards an ideal COX-2 inhibitor lead, RSC Advances, 2024.
- Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis, New England Journal of Medicine, 2016.
- Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials, Journal of Internal Medicine, 2022.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
